UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 599

Sortiert nach

Editorial: are additional tests needed to predict sustained virologic response in hepatitis C treated with interferon‐free direct‐acting antiviral combinations?

Alimentary pharmacology & therapeutics, 2018-03, Vol.47 (6), p.848-849

Ferenci, P.

2018

Link zum Volltext

Verfügbarkeit prüfen

Review article: diagnosis and current therapy of Wilson's disease

Alimentary pharmacology & therapeutics, 2004-01, Vol.19 (2), p.157-165

Ferenci, P

2004

Link zum Volltext

Verfügbarkeit prüfen

Clinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study

Gut, 2007-01, Vol.56 (1), p.115-120

2007

Link zum Volltext

Verfügbarkeit prüfen

Commentary: triple therapy for patients with chronic hepatitis C and advanced fibrosis?

Alimentary pharmacology & therapeutics, 2013-12, Vol.38 (11-12), p.1407-1408

Ferenci, P.

2013

Link zum Volltext

Verfügbarkeit prüfen

Optimal treatment duration for patients with HCV genotype 1 infection

Journal of viral hepatitis, 2012-01, Vol.19 (s1), p.7-13

Ferenci, P.

2012

Link zum Volltext

Verfügbarkeit prüfen

Commentary: proteomics and drug-induced liver injury

Alimentary pharmacology & therapeutics, 2012-03, Vol.35 (6), p.740-741

Ferenci, P.

2012

Link zum Volltext

Verfügbarkeit prüfen

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

Journal of hepatology, 2019-05, Vol.70 (5), p.1008-1015

2019

Link zum Volltext

Verfügbarkeit prüfen

Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies

Journal of antimicrobial chemotherapy, 2004-01, Vol.53 (1), p.15-18

FERENCI, Peter

2004

Link zum Volltext

Verfügbarkeit prüfen

Quantitative trace element mapping in liver tissue from patients with Wilson`s disease determined by micro X-ray fluorescence

Journal of trace elements in medicine and biology, 2019-01, Vol.51, p.42-49

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of patatin‐like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension

Alimentary pharmacology & therapeutics, 2018-08, Vol.48 (4), p.451-459

2018

Link zum Volltext

Verfügbarkeit prüfen

Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis

Gut, 2014-07, Vol.63 (7), p.1033-1034

2014

Link zum Volltext

Verfügbarkeit prüfen

Review article: genetic factors that modify the outcome of viral hepatitis

Alimentary pharmacology & therapeutics, 2014-05, Vol.39 (10), p.1059-1070

2014

Link zum Volltext

Verfügbarkeit prüfen

Von Willebrand Factor as a new marker for non‐invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C

Alimentary pharmacology & therapeutics, 2014-02, Vol.39 (3), p.331-338

2014

Link zum Volltext

Verfügbarkeit prüfen

Predictors of Response to Therapy for Chronic Hepatitis C

Seminars in liver disease, 2004-01, Vol.24 (S 2), p.25-31

Ferenci, Peter

2004

Link zum Volltext

Verfügbarkeit prüfen

ESPEN Guidelines on Enteral Nutrition: Liver disease

Clinical nutrition (Edinburgh, Scotland), 2006-04, Vol.25 (2), p.285-294

2006

Link zum Volltext

Verfügbarkeit prüfen

Interferon‐free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses

Alimentary pharmacology & therapeutics, 2015-09, Vol.42 (6), p.707-718

2015

Link zum Volltext

Verfügbarkeit prüfen

Polymorphisms of interferon- lambda 4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C

Alimentary pharmacology & therapeutics, 2014-01, Vol.39 (1), p.104-111

2014

Link zum Volltext

Verfügbarkeit prüfen

Successful anti‐viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C

Alimentary pharmacology & therapeutics, 2015-03, Vol.41 (6), p.521-531

2015

Link zum Volltext

Verfügbarkeit prüfen

Polymorphisms of interferon‐λ4 and IL28B – effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C

Alimentary pharmacology & therapeutics, 2014-01, Vol.39 (1), p.104-111

2014

Link zum Volltext

Verfügbarkeit prüfen

Commentary: durability of SVR in chronic hepatitis C patients treated with peginterferon‐a2a/ribavirin in combination with a direct‐acting anti‐viral – authors’ reply

Alimentary pharmacology & therapeutics, 2013-09, Vol.38 (5), p.558-558

2013

Link zum Volltext

Verfügbarkeit prüfen

Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation

Journal of clinical pathology, 2006-03, Vol.59 (3), p.246-249

2006

Link zum Volltext

Verfügbarkeit prüfen

Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial

Journal of viral hepatitis, 2015-08, Vol.22 (8), p.651-657

2015

Link zum Volltext

Verfügbarkeit prüfen

Letter: comparing scoring systems and outcome of patients admitted to a liver intensive care unit with severe variceal bleeding

Alimentary pharmacology & therapeutics, 2014-10, Vol.40 (7), p.856-856

2014

Link zum Volltext

Verfügbarkeit prüfen

Revisiting the Predictors of a Sustained Virologic Response in the Era of Direct-Acting Antiviral Therapy for Hepatitis C Virus

Clinical infectious diseases, 2013-01, Vol.56 (1), p.118-122

2013

Link zum Volltext

Verfügbarkeit prüfen

Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks? Authors' reply

Alimentary pharmacology & therapeutics, 2014-03, Vol.39 (5), p.549-550

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 599

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(561)
Mit Volltextzugriff
(507)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(263)
Science & Technology
(257)
Life Sciences & Biomedicine
(256)
Female
(171)
Male
(171)
Biological And Medical Sciences
(153)
Gastroenterology & Hepatology
(152)
Adult
(150)
Medical Sciences
(148)
Middle Aged
(135)
Gastroenterology And Hepatology
(125)
Aged
(80)
Hepatitis C, Chronic - Drug Therapy
(70)
Gastroenterology. Liver. Pancreas. Abdomen
(62)
Antiviral Agents - Therapeutic Use
(60)
Infectious Diseases
(60)
Treatment Outcome
(57)
Interferon-Alpha - Therapeutic Use
(52)
Drug Therapy, Combination
(51)
Ribavirin - Therapeutic Use
(51)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Editorial: are additional tests needed to predict sustained virologic response in hepatitis C treated with interferon‐free direct‐acting antiviral combinations?

Review article: diagnosis and current therapy of Wilson's disease

Clinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study

Commentary: triple therapy for patients with chronic hepatitis C and advanced fibrosis?

Optimal treatment duration for patients with HCV genotype 1 infection

Commentary: proteomics and drug-induced liver injury

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies

Quantitative trace element mapping in liver tissue from patients with Wilson`s disease determined by micro X-ray fluorescence

Impact of patatin‐like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension

Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis

Review article: genetic factors that modify the outcome of viral hepatitis

Von Willebrand Factor as a new marker for non‐invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C

Predictors of Response to Therapy for Chronic Hepatitis C

ESPEN Guidelines on Enteral Nutrition: Liver disease

Interferon‐free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses

Polymorphisms of interferon- lambda 4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C

Successful anti‐viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C

Polymorphisms of interferon‐λ4 and IL28B – effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C

Commentary: durability of SVR in chronic hepatitis C patients treated with peginterferon‐a2a/ribavirin in combination with a direct‐acting anti‐viral – authors’ reply

Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation

Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial

Letter: comparing scoring systems and outcome of patients admitted to a liver intensive care unit with severe variceal bleeding

Revisiting the Predictors of a Sustained Virologic Response in the Era of Direct-Acting Antiviral Therapy for Hepatitis C Virus

Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks? Authors' reply

Suchergebnisse filtern